• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Hep par-1:一种用于鉴别肝细胞癌与转移性癌的新型免疫组化标志物。

Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.

作者信息

Hanif Razia, Mansoor Samina

机构信息

Department of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore.

出版信息

J Coll Physicians Surg Pak. 2014 Mar;24(3):186-9.

PMID:24613115
Abstract

OBJECTIVE

To evaluate the diagnostic utility of Hep par-1 in differentiating hepatocellular carcinoma from metastatic carcinoma taking histopathology as a gold standard.

STUDY DESIGN

Comparative cross-sectional study.

PLACE AND DURATION OF STUDY

Pathology Department, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, from April 2007 to February 2008.

METHODOLOGY

Hep par-1 immunohistochemical stain was performed on 60 cases of liver carcinoma, 30 cases each of metastatic and hepatocellular carcinoma. Information regarding patient age, gender, sign and symptoms, radiographic findings, histological grade of tumour, and expression of Hep par-1 on hepatocellular and metastatic carcinoma were recorded on proforma sheet. Sensitivity, specificity, positive and negative predictive values, and accuracy of Hep par-1 were calculated using the formulas.

RESULTS

Hep par-1 expression was noted in 25 out of 30 cases of hepatocellular carcinoma (83%). Out of 30 cases of metastatic carcinoma, only one case expressed staining in < 5% tumour cells and remaining 29 cases showed no reactivity. The age of the patients with hepatocellular carcinoma ranged from 40 to 76 years with a median age of 60.5 years and 40 - 75 years for metastatic carcinomas with a median age of 57.5 years.

CONCLUSION

Hep par-1 is a reliable immunohistochemical marker for cases of hepatocellular carcinoma (HCC). It can be used along with other markers in morphologically difficult cases when differential diagnosis lies between poorly differentiated HCC and metastatic carcinoma of liver.

摘要

目的

以组织病理学为金标准,评估Hep par-1在鉴别肝细胞癌与转移癌中的诊断效用。

研究设计

比较性横断面研究。

研究地点及时间

2007年4月至2008年2月,拉合尔绍卡特·汗姆纪念癌症医院及研究中心病理科。

方法

对60例肝癌病例进行Hep par-1免疫组化染色,其中转移癌和肝细胞癌各30例。将患者年龄、性别、体征和症状、影像学检查结果、肿瘤组织学分级以及Hep par-1在肝细胞癌和转移癌中的表达情况记录在表格中。使用公式计算Hep par-1的敏感性、特异性、阳性和阴性预测值以及准确性。

结果

30例肝细胞癌中有25例(83%)出现Hep par-1表达。30例转移癌中,仅1例在<5%的肿瘤细胞中出现染色,其余29例无反应。肝细胞癌患者年龄在40至76岁之间,中位年龄为60.5岁;转移癌患者年龄在40至75岁之间,中位年龄为57.5岁。

结论

Hep par-1是肝细胞癌(HCC)病例的可靠免疫组化标志物。当形态学诊断困难,鉴别诊断在于低分化HCC和肝转移癌时,它可与其他标志物联合使用。

相似文献

1
Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.Hep par-1:一种用于鉴别肝细胞癌与转移性癌的新型免疫组化标志物。
J Coll Physicians Surg Pak. 2014 Mar;24(3):186-9.
2
Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.抗肝细胞克隆OCH1E5(Hep Par 1)在肝肿瘤组织学评估中的应用。
Indian J Pathol Microbiol. 2006 Jul;49(3):341-4.
3
The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.肝细胞石蜡1抗体在免疫组织学上鉴别肝细胞癌与胆管癌及转移癌中的应用。
Malays J Pathol. 2006 Dec;28(2):87-92.
4
Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1.单发性小肝细胞癌的免疫组织学评估,单克隆抗体肝细胞石蜡1染色阴性
J Surg Oncol. 2004 Nov 1;88(2):104-7. doi: 10.1002/jso.20144.
5
Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.Hep Par 1及相关抗体在肝细胞癌与胆管癌、混合性肿瘤及转移性癌的免疫组织学鉴别诊断中的应用
Histopathology. 1998 Oct;33(4):318-24. doi: 10.1046/j.1365-2559.1998.00522.x.
6
Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.肝细胞癌、胆管癌和转移性腺癌的免疫组织化学比较特征
Hum Pathol. 2002 Dec;33(12):1175-81. doi: 10.1053/hupa.2002.130104.
7
Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.磷脂酰肌醇蛋白聚糖-3在鉴别肝细胞癌与其他肝脏肿瘤方面有用,但并不优于肝细胞石蜡1(抗体)。
Malays J Pathol. 2016 Dec;38(3):229-233.
8
Immunoreactivity of hepatocyte paraffin 1 monoclonal antibody in cutaneous metastatic tumors.肝细胞石蜡1单克隆抗体在皮肤转移性肿瘤中的免疫反应性
Am J Clin Pathol. 2004 Jul;122(1):85-9. doi: 10.1309/1GUH-U5LK-2A82-JTJR.
9
Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma.用于肝细胞癌诊断的5种肝细胞分化免疫组化标志物的比较
Arch Pathol Lab Med. 2015 Aug;139(8):1028-34. doi: 10.5858/arpa.2014-0479-OA.
10
The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.arginase-1 免疫染色在鉴别肝细胞癌与转移性癌和胆管细胞癌中的诊断价值与 HepPar-1 相比。
Diagn Pathol. 2012 Oct 30;7:149. doi: 10.1186/1746-1596-7-149.

引用本文的文献

1
Seminal vesicle metastasis from hepatocellular carcinoma and renal cell carcinoma.来自肝细胞癌和肾细胞癌的精囊转移
Urol Ann. 2023 Apr-Jun;15(2):235-237. doi: 10.4103/ua.ua_123_22. Epub 2023 Feb 14.
2
Heterogeneity of antigenic constellation in human hepatocellular carcinoma.人类肝细胞癌中抗原组的异质性。
Exp Ther Med. 2021 Mar;21(3):270. doi: 10.3892/etm.2021.9701. Epub 2021 Jan 25.
3
A Translational Hepatic Artery Infusion (HAI) Model for Hepatocellular Carcinoma in Woodchucks.一种用于土拨鼠肝细胞癌的转化性肝动脉灌注(HAI)模型。
J Surg Res. 2020 Jul;251:126-136. doi: 10.1016/j.jss.2020.02.002. Epub 2020 Mar 3.
4
The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.精氨酸酶-1、FTCD和MOC-31表达在肝细胞癌(HCC)早期检测及HCC与肝转移性腺癌鉴别诊断中的诊断价值
J Gastrointest Cancer. 2020 Mar;51(1):88-101. doi: 10.1007/s12029-019-00211-2.